Press Enter to search · ESC to close

Macro

Baili Tianheng’s Yizekang EGFR×HER3 ADC Added to China’s 2026 National Reimbursement Drug List

Baili Tianheng’s self-developed Yizekang (iza-bren), the world’s first and only approved EGFR×HER3 bispecific antibody-drug conjugate, was added to China’s 2026 National Reimbursement Drug List following national price negotiations, the list was announced on November 14 at the 2026 National Innovative Drug High-Quality Development Conference. A newly introduced pre-declaration mechanism let the drug enter reimbursement in its first year on the market. The updated list takes effect January 1, 2027.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback